Have you registered for our next webinar? If not, there's still time! Reserve your seat today.
Accumetrics is truly at the forefront of revolutionizing the way physicians measure millions of patients who take antiplatelet drugs to prevent cardiovascular and cerebrovascular events.
These patients may have been prescribed antiplatelet medications (e.g. aspirin, clopidogrel*) to help prevent heart attacks, stroke and other potentially life-threatening cardiovascular events.1
However, studies have shown that up to 1 in 3 patients may not respond adequately to their antiplatelet medications.2 Patients who do not respond adequately to their antiplatelet therapies may be at significantly greater risk of ischemic events and death.3-6
Accumetrics, a privately-held company based in San Diego, CA, develops, manufactures, and markets the VerifyNow® System, a state-of-the-art platform and comprehensive suite of tests for the assessment of platelet reactivity to all major antiplatelet therapies in minutes.
Today, approximately half of the top 50 U.S. heart hospitals utilize the rapid and easy-to-use VerifyNow System to provide physicians with reliable information to help them understand their patients’ platelet reactivity.9
*Clopidogrel is the generic name for the branded drug, Plavix. Plavix is a registered trademark of Bristol Myers Squibb/Sanofi Pharmaceuticals Partnership.
To provide patients and healthcare professionals the highest quality clinical evidence that will allow for improved management of cardiovascular disease. Through offering products and services that are of the highest quality, we will continually strive to exceed the expectations of our customers, our shareholders and our employees.
Our Mission is to establish the Accumetrics suite of products as the standard of care in tailoring medical therapy to the benefits of patients at risk of cardiovascular disease worldwide.